Multiple molecular pathways (N/A)

The term "Multiple molecular pathways" does not refer to a single, discrete therapeutic target such as a specific protein, receptor, or enzyme. Instead, it is a broad pharmacological descriptor used to characterize drugs or interventions that exert their effects by modulating several distinct biological signaling cascades simultaneously (Hopkins, A. L., 2008, Nature Chemical Biology). This concept is central to the field of polypharmacology, where the therapeutic outcome is the result of a drug's interaction with a network of targets rather than a single molecular entity (Anighoro, A., et al., 2014, Journal of Medicinal Chemistry). Such multi-target approaches are frequently employed in the treatment of complex, multifactorial diseases like cancer and metabolic syndrome, where biological redundancy often allows cells to bypass the inhibition of a single pathway (Guaman-Ortiz, L. M., et al., 2017, International Journal of Molecular Sciences). Because this term encompasses a wide variety of unrelated biological processes, it lacks a unique molecular classification, a specific UniProt identifier, or a singular biochemical function. Drugs often associated with this description include multi-kinase inhibitors like Sorafenib or pleiotropic agents like Metformin, which influence various metabolic and growth-related pathways (Reddy, A. S., & Zhang, S., 2013, Frontiers in Genetics). Consequently, this entry is classified as incorrect for the purposes of structured target identification as it represents a mechanism of action or a systems-level observation rather than a specific target.

Other names

PolypharmacologyMulti-target mechanismPleiotropic signaling pathwaysNetwork pharmacology

Modulation of multiple distinct signaling cascades and molecular targets simultaneously to achieve a therapeutic effect.